IHAC
IHAC is an inhibitor HSP90-anchoring chimera, that covalently binds BRD4 ligand (+) -JQ-1 to HSP90, and inhibits the proliferation of cancer cells. iHAC activates the anti-tumor immune response, inhibits the recurrence and metastasis of 4T1 breast cancer in mouse models[1].
Product Specifications
UNSPSC
12352005
Target
Epigenetic Reader Domain
Related Pathways
Epigenetics
Field of Research
Cancer
Smiles
ClC1=CC=C(C2=N[C@@H](CC(NCC3=CN(CCCC(N(CC#N)S(=O)(C4=CC=C(C(NCCCN5C(SC6=CC(OCO7)=C7C=C6I)=NC8=C(N)N=CN=C85)=O)C=C4)=O)=O)N=N3)=O)C9=NN=C(C)N9C%10=C2C(C)=C(C)S%10)C=C1
Molecular Formula
C50H46ClIN16O7S3
Molecular Weight
1241.56
References & Citations
[1]Chen Y, et al., Engineered platelets as targeted protein degraders and application to breast cancer models. Nat Biotechnol. 2024 Dec 3. Epub ahead of print. Erratum in: Nat Biotechnol. 2025 Jan 13.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC740181-500 1x 500 µL
CD59 (heavy chain of Protectin) (BRA-10G), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400003-100 1x 100 µL
CD45RO (UCHL-1), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680178-500 1x 500 µL
CD50 (ICAM-3) (186-2G9), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details